Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies

Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies

Anastasia Gkiala,1 Sotiria Palioura2 1National and Kapodistrian University of Athens School of Medicine, Athens, Greece; 2Athens Vision Eye Institute, Athens, GreeceCorrespondence: Sotiria PaliouraAthens Vision Eye Institute, 328-330 Syngrou Ave., Kallithea, Athens 17673, GreeceTel +30 698 580 2355E...

Full description

Bibliographic Details
Main Authors:	Gkiala A, Palioura S
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-10-01
Series:	Clinical Ophthalmology
Subjects:	immune checkpoint inhibitors braf inhibitors mek inhibitors ctla4 inhibitors pd1 inhibitors c-kit mutations braf mutations nras mutations dabrafenib vemurafenib trametinib ipilimumab pembrolizumab nivolumab
Online Access:	https://www.dovepress.com/conjunctival-melanoma-update-on-genetics-epigenetics-and-targeted-mole-peer-reviewed-article-OPTH

Similar Items

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
by: Stefanie Hoyer, et al.
Published: (2021-11-01)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
by: Wolfram Samlowski, et al.
Published: (2021-11-01)

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
by: Gabriele Madonna, et al.
Published: (2021-08-01)

MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
by: Tran KA, et al.
Published: (2015-12-01)

Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
by: Wei Wang, et al.
Published: (2021-09-01)

Comparative analysis of adjuvant therapy for stage III BRAF‐mut melanoma: A real‐world retrospective study from single center in China
by: Jingqin Zhong, et al.
Published: (2023-05-01)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
by: Clare Judith Stones, et al.
Published: (2013-05-01)

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
by: Markus V. Heppt, et al.
Published: (2017-08-01)

MEK inhibition and immune responses in advanced melanoma
by: Reinhard Dummer, et al.
Published: (2017-08-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
by: Francesca Consoli, et al.
Published: (2020-07-01)

Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma
by: JIANG Jianyun, YING Hongmei
Published: (2022-05-01)

Non-small-cell lung cancer: how to manage BRAF-mutated disease
by: Giorgia Guaitoli, et al.
Published: (2023-05-01)

Therapeutic Potential of Black Pepper Compound for BRaf Resistant Melanoma
by: Neel M. Fofaria, et al.
Published: (2017-11-01)

Bilateral multifocal central serous retinopathy due to management of metastatic melanoma with BRAf MEK inhibitors: Case report
by: Grisma Patel, et al.
Published: (2023-03-01)

Efficacy of Targeted Radionuclide Therapy Using [<sup>131</sup>I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma
by: Hussein Akil, et al.
Published: (2021-03-01)

Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
by: Weart TC, et al.
Published: (2018-04-01)

Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
by: Sandip Ganguly, et al.
Published: (2021-09-01)

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
by: Maximilian Haist, et al.
Published: (2022-04-01)

Targeting the RAS pathway by mitogen-activated protein kinase inhibitors
by: Michael Kiessling, et al.
Published: (2015-12-01)

Drug-induced hypersensitivity syndrome like reaction with angioedema and hypotension associated with BRAF inhibitor use and antecedent immune checkpoint therapy
by: Jasmine Rana, MD, et al.
Published: (2021-07-01)

Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
by: Taku Fujimura, et al.
Published: (2019-09-01)

Lack of Influence of Non-Overlapping Mutations in <i>BRAF</i>, <i>NRAS</i>, or <i>NF1</i> on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma
by: Alyssa Panning, et al.
Published: (2023-07-01)

By what way Physician can Enhance Outcomes in Patients with metastatic Malignant Melanoma
by: Mehrdad Payandeh, et al.
Published: (2012-03-01)

By what way Physician can Enhance Outcomes in Patients with metastatic Malignant Melanoma
by: Mmohammad Erfan Zare, et al.
Published: (2012-01-01)

Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation
by: Yukiko Kiniwa, et al.
Published: (2021-03-01)

The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
by: Silvia Mezi, et al.
Published: (2023-09-01)

Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC
by: Bruce E. Johnson, MD, et al.
Published: (2022-05-01)

Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
by: Vincenzo Di Nunno, et al.
Published: (2023-01-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
by: Justin C. Moser, et al.
Published: (2019-12-01)

Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
by: Stephen A. Luebker, et al.
Published: (2019-04-01)

ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells
by: Giulia Cesi, et al.
Published: (2017-06-01)

Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma
by: Heike Niessner, et al.
Published: (2023-11-01)

Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
by: Francisco Meraz-Torres, et al.
Published: (2024-01-01)

BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways
by: Peng Yue, et al.
Published: (2019-01-01)

Two Case Reports of Rare BRAF Mutations in Exon 11 and Exon 15 with Discussion of Potential Treatment Options
by: Georg Richtig, et al.
Published: (2016-09-01)

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
by: Anna Stagno, et al.
Published: (2021-05-01)

Systemic Therapy of Metastatic Melanoma: On the Road to Cure
by: Julian Steininger, et al.
Published: (2021-03-01)

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
by: Dahlia Fedele, et al.
Published: (2024-01-01)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
by: Gulietta M. Pupo, et al.
Published: (2017-05-01)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
by: Karisa C. Schreck, et al.
Published: (2019-08-01)